TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
KOD

Kodiak Sciences Inc

Healthcare · Biotechnology

32.90$ +0.2% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Kodiak Sciences Inc (KOD)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 62.9% of the shares are freely tradable; institutional investors hold 99.6%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 99.6%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 5.2%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 62.9%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 27.2%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 63Mio.

Largest Shareholders

Institutions

Institutions KOD
Name Stake (%) Shares Change (%) Date
Baker Bros Advisors LP 31.69 19,919,186 +0.0 03/31/2026
BlackRock Inc 6.26 3,935,302 -0.5 03/31/2026
State Street Corp 3.58 2,250,920 +30.0 03/31/2026
T. Rowe Price Associates, Inc. 3.24 2,039,350 +74.3 03/31/2026
BRAIDWELL LP 2.89 1,818,665 -12.3 03/31/2026
Vanguard Capital Management, LLC 2.73 1,717,076 +0.0 03/31/2026
The Goldman Sachs Group Inc 2.69 1,689,003 +29.6 03/31/2026
RTW INVESTMENTS, LLC 2.37 1,487,934 +0.0 03/31/2026
TCG Crossover Management, LLC 2.30 1,445,538 +0.0 06/30/2026

Funds

Funds KOD
Name Stake (%) Shares Change (%) Date
State Street® SPDR® S&P® Biotech ETF 2.51 1,577,932 -1.1 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?